Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This can come back towards $1.00 again. I like this play very much
REBOUND..up again like to see $ 7 above eod
absolutely right...under CAN$ 3...soon
...back under 3 ???
..this product is ready for the market and will be sold worldwide
https://www.chf-solutions.com/aquadex-flexflow/
imo $ 40 eoy is realistic...
this is NO pump and dump
https://www.chf-solutions.com/about-us/newsroom/
this is like a Block Buster ..Million-Dollar- Market ahead
DE000A1TNV91
.up to moon
Perceptive Advisors LLC bought a new position in shares of Stemline Therapeutics during the fourth quarter worth $115,000. Bogle Investment Management L P DE bought a new position in shares of Stemline Therapeutics during the fourth quarter worth $1,015,000. Renaissance Technologies LLC raised its position in shares of Stemline Therapeutics by 7.9% in the fourth quarter. Renaissance Technologies LLC now owns 65,500 shares of the biopharmaceutical company’s stock worth $701,000 after buying an additional 4,800 shares during the period. Finally, J. Goldman & Co LP bought a new position in shares of Stemline Therapeutics during the fourth quarter worth $2,139,000. Institutional investors own 37.76% of the company’s stock.
Stemline Therapeutics Inc (NASDAQ:STML) has been given a $41.00 price objective by analysts at Ladenburg Thalmann Financial Services in a report issued on Monday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Ladenburg Thalmann Financial Services’ target price indicates a potential upside of 327.08% from the company’s current price.
HUGE NEWS
Completes Stage 3 Enrollment
Stemline has completed enrollment of the Stage 3 cohort of the SL-401 pivotal trial in BPDCN. Stage 3 enrolled 13 first-line BPDCN patients; statistical analysis will be based on evaluable first-line patients. The registration pathway was previously agreed upon with the U.S. Food and Drug Administration (FDA). Depending on the data from the trial, Stemline plans to use the results generated to support the potential filing of a Biologics License Application (BLA) for full approval in first-line BPDCN, and is targeting possible BLA filing in the second half of this year.
..there is brewing something big...whole board of directors has acquired shares...
https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001390478&owner=include&count=40
a Buy rating on GALE, with a price target of $11.00, which represents a potential upside of 431% from where the stock is currently trading.....
https://www.smarteranalyst.com/2017/01/09/stock-update-nasdaqgale-galena-biopharma-inc-provides-update-abstral-investigation/
Two Biotechnology Names Are Hot: Galena Biopharma, Inc. (GALE), Ophthotech Corporation (OPHT)
By Iris Howard -
January 24, 2017
http://theindependentrepublic.com/2017/01/24/two-biotechnology-names-are-hot-galena-biopharma-inc-gale-ophthotech-corporation-opht/
Galena Biopharma shares jump 26% after news that drug will enter late-stage trial
http://www.marketwatch.com/story/galena-biopharma-shares-jump-26-after-news-that-drug-will-enter-late-stage-trial-2016-12-28-991421
BREAK OUR ALERT !!!!
BNTC has another major catalyst gas approaching Jan 27th. Don't want to be on the sidelines when full details are disclosed.
$ 10 billion market..
http://www.ariva.de/news/benitec-receives-orphan-drug-designation-in-the-european-6008384
this news is worth about $ 5 per share..
3.95 again this want higher.........
and no one has understood what is happening here..HUGE stay long....
these shorts are getting screwed haha
... $ 4.5 eod SQEEZE...................
huge news ..this is great..
now expects to plan the path for a final "pivotal trial" with the US health authority FDA in the first quarter of 2017
premarket looking promising...gap close...
my prediction til eow is gap close about 32 $
Albireo now expects to plan the path for a final "pivotal trial" with the US health authority FDA in the first quarter of 2017, on the basis of which an authorization application for the drug could be submitted
SQUEEZE !!!![color=red][/color]
SQUEEZE..
$ 10 eoy !!!
older file but still valid
https://www.sec.gov/Archives/edgar/data/1425565/000119312515262898/d52211dsc13da.htm
“With this offering, we expect to report positive stockholders’ equity and working capital at the end of the year,” said RGS Energy CEO Dennis Lacey. “
http://www.conferencecalltranscripts.org/8/summary/?id=3319813